Projects
The potential of Lactobacillus exopolysaccharides and glycoproteins as safe vaccine adjuvants. University of Antwerp
LNP-DECODE: Deciphering the adjuvants activity of lipid nanoparticle-based mRNA vaccines in primary dendritic cells Ghent University
This project aims to put UGent at the forefront of mRNA-vaccine research by providing in-depth insights in the adjuvant properties of LNP-based mRNA-vaccines. To this end, we will join the expertise of 3 teams working on dendritic cell biology, nucleic acid sensors and lipid nanoparticles respectively.This consortium will form the basis for the development of vaccines against autoimmune diseases.
Unravelling the anti-tumor effect of autologous myeloid dendritic cel Is plus the synthetic adjuvant AS01B in solid tumors. Vrije Universiteit Brussel
prevents long-term disease control in only a small percentage of patients, and still shows the large
progressive disease. The lack of myeloid dendritic cells (myDCs) in the microenvironment
tumor (TME) has a negative influence on the therapy response, Recent research shows that an adjuvant
called AS01s (vaccine) recruits ...
Investigation into the efficacy of IL-1b AcTaleukins as adjuvant for cancer immunotherapy. Ghent University
The Interleukin-1 (IL-1) family consists of a group of cytokines with potent immuno-stimulatory
activities. Several studies indicate that activation of leukocyte subsets by IL-1 is essential for
protective immunity against a variety of pathogens and for elimination of cancer cells. IL-1 could
have therapeutic value, for instance as vaccine adjuvant, yet its clinical application is hampered by
the ...
Addition of WT1 mRNA-loaded autologous dendritic cell immunotherapy to adjuvant temozolomide chemotherapy after maximal, safe surgical resection and chemoradiation for newly diagnosed glioblastoma patients. University of Antwerp
The working mechanism of a new class of adjuvant, the Layered Double Hydroxide (LDH) family. Ghent University
This interdisciplinary project combines key aspects of chemistry and immunology to predict which members of a new class of adjuvants, the Layered double hydroxide family (LDH), induce a better cellular and/or humoral immune response than the common used adjuvant alum. Besides, we will unravel their cellular and molecular mechanism of action and their applicability in an influenza infection model.
Vaccine for prevention and treatment of Trypanosoma cruzi infection (CRUZIVAX). University of Antwerp
Feasibility and safety of a WT1-targeted cancer vaccine in patients with malignant mesothelioma and locally advanced breast cancer: an open label phase I trial. University of Antwerp
NMR and molecular modelling investigations of hydroxyl apatite – DNA immunestimulator nanoplatforms for improved vaccine delivery Ghent University
There is an urgent need for safe vaccines against many dangerous diseases; however, avoiding side effects is a major prerequisite in ensuring patient compliance. To address this, new generation vaccines with safe but weakly immunogenic antigens are formulated together with carriers and/or adjuvants to induce the desired immunological response. The use of nanoparticles as carriers for vaccines, also known as nanovaccinology, is a promising ...